Bach Pharma, Inc. is dedicated to the development and commercialization of new therapeutics for the treatment of life - threatening Neurodegenerative Diseases.

 

Bach Pharma, Inc., a privately held company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life-threatening diseases. Bach’s lead program is targeting degenerative neurological illnesses with the goal to dramatically improve patients' lives and reduce the cost of global health care.

The company's lead candidate, GVT®, is a novel cytoprotective agent with promising powerful anti-oxidant and anti-inflammatory properties.  GVT has the potential to treat serious diseases of the central nervous and immune systems, as many are associated with oxidative stress and inflammatory pathways. 

BACH has several issued patents on the use of GVT for various indications and several pending for use and manufacturing processes. This intellectual property (IP) and further planned submissions for GVT and other phthalazinedione derivatives will support the long-term development and commercialization of these therapeutics.

BACH is commited to forming unique partnerships and collaborations to advance this important class of drugs through the clinic and to patients worldwide. BACH is dedicated to the cardinal principles of scientific excellence and to the highest standards of ethics and integrity. BACH realized that success depends on creating the environment necessary to nourish integrity, knowledge, imagination, skill, diversity and teamwork in our employees and our strategic partners.

 

 

NEWS & EVENTS


Upcoming Events

Special Shareholder Meeting            North Andover, MA                             June 20, 2016

800 Turnpike St, Suite 300                               North Andover, MA 01845

Board of Directors Meeting:             North Andover, MA

June 20, 2016

800 Turnpike St, Suite 300                               North Andover, MA 01845

Press Releases

August 3, 2016

Bach Pharma Announces Appointment of Dr. Pravin Chaturvedi to Board of Directors

July 5, 2016

Bach Pharma appoints Kelly Blackburn as Chief Executive Officer

January 30, 2016

          Possible Hope for Veterans Suffering               from Gulf War Illness

February 10, 2013

Bach Pharma Appoints William S. Lynn as Lifetime Director Emeritus

February 1, 2013

Bach Pharma Appoints Mr. Dan Cato as President

June 30, 2011

Positive Progress for Bach Pharma

April 20, 2011

Foundation for the NIH Launches First U.S-Russia Scientific Forum

January 4, 2010

Bach Pharma announces Preventative Drug Development Program

Newsletters

June 2014